Circulating proteinic biomarkers and breast cancer;Marqueurs protéiques circulants et cancer du sein

Gynecologie Obstetrique et Fertilite

Volumn 34, Issue 7-8, 2006, Pages 638-646

  Mathelin, C ^a,b   Koehl, C ^a   Rio, M C ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Biomarkers; Breast cancer; CA 15.3; HER2; TFF1

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CANCER ASSOCIATED ANTIGEN 549; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KERATIN; MUCIN 1; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; POLYMORPHIC EPITHELIAL MUCIN; TREFOIL PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CYTODIAGNOSIS; DISEASE MARKER; FOLLOW UP; GENE OVEREXPRESSION; PROGNOSIS; PROTEIN URINE LEVEL;

EID: 33747075844     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2006.06.011     Document Type: Article

References (60)

1. Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265 25 (1990) 15286-15293
2. Regimbald L.H., Pilarski L.M., Longenecker B.M., Reddish M.A., Zimmermann G., and Hugh J.C. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56 18 (1996) 4244-4249
3. Granowska M., Mather S.J., Jobling T., Naeem M., Burchell J., Taylor-Papadimitriou J., et al. Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours. Int. J. Biol. Markers 5 2 (1990) 89-96
4. Gourevitch M.M., von Mensdorff-Pouilly S., Litvinov S.V., Kenemans P., van Kamp G.J., Verstraeten A.A., et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br. J. Cancer 72 4 (1995) 934-938
5. Bast Jr. R.C., Ravdin P., Hayes D.F., Bates S., Fritsche Jr. H., Jessup J.M., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19 6 (2001) 1865-1878
6. Beveridge R.A. Review of clinical studies of CA 27.29 in breast cancer management. Int. J. Biol. Markers 14 1 (1999) 36-39
7. Gion M., Mione R., Leon A.E., and Dittadi R. Comparison of the diagnostic accuracy of CA27.29 and CA 15.3 in primary breast cancer. Clin. Chem. 45 5 (1999) 630-637
8. Graham R.A., Burchell J.M., and Taylor-Papadimitriou J. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol. Immunother. 42 2 (1996) 71-80
9. Fung P.Y., and Longenecker B.M. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 51 4 (1991) 1170-1176
10. Seregni E., Coli A., and Mazzucca N. Circulating tumour markers in breast cancer. Eur. J. Nucl. Med. Mol. Imaging 31 Suppl. 1 (2004) S15-S22
11. Keydar I., Chou C.S., Hareuveni M., Tsarfaty I., Sahar E., Selzer G., et al. Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. Proc. Natl. Acad. Sci. USA 86 4 (1989) 1362-1366
12. Oosterkamp H.M., Scheiner L., Stefanova M.C., Lloyd K.O., and Finstad C.L. Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Int. J. Cancer 72 1 (1997) 87-94
13. Hilkens J., Buijs F., Hilgers J., Hageman P., Calafat J., Sonnenberg A., et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer 34 2 (1984) 197-206
14. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., and Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3 3 (1984) 223-232
15. Huber P.R., Bischof P., Kretschmer R., Truschnig M., Halwachs G., and Schmidt M. CA 15.3: a multicentre evaluation of automated and manual tests. Eur. J. Clin. Chem. Clin. Biochem. 34 1 (1996) 77-84
16. Anaes publications. Marqueurs sériques dans les cancers du sein et les cancers colorectaux. http://www.anaes.fr/anaes/Publications/ 1997.
17. Lelle R.J., Henkel E., Leinemann D., and Goeschen K. Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol. Obstet. Invest. 27 3 (1989) 137-142
18. Devine P.L., Duroux M.A., Quin R.J., McGuckin M.A., Joy G.J., Ward B.G., et al. CA 15.3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Breast Cancer Res. Treat. 34 3 (1995) 245-251
19. Giai M., Roagna R., Ponzone R., Biglia N., Sgro L., Perona M., et al. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res. 16 2 (1996) 875-881
20. De La Lande B., Hacene K., Floiras J.L., Alatrakchi N., and Pichon M.F. Prognostic value of CA 15.3 kinetics for metastatic breast cancer. Int. J. Biol. Markers 17 4 (2002) 231-238
21. Blijlevens N.M., Oosterhuis W.P., Oosten H.R., and Mulder N.H. Clinical value of TPS, CEA and CA 15.3 in breast cancer patients. Anticancer Res. 15 6B (1995) 2711-2716
22. Schuurman J.J., Bong S.B., and Einarsson R. Determination of serum tumor markers TPS and CA 15.3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res. 16 4B (1996) 2169-2172
23. Antoine E., Kayitalire L., and Spielmann M. [CA 15.3 and breast cancer]. Rev. Med. Interne 15 10 (1994) 650-662
24. Martoni A., Zamagni C., Bellanova B., Zanichelli L., Vecchi F., Cacciari N., et al. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur. J. Cancer 31A 10 (1995) 1615-1621
25. Depres-Brummer P., Itzhaki M., Bakker P.J., Hoek F.J., Veenhof K.H., and de Wit R. The usefulness of CA 15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 121 7 (1995) 419-422
26. Willsher P.C., Beaver J., Blamey R.W., and Robertson J.F. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Anticancer Res. 15 4 (1995) 1609-1611
27. Soletormos G., Nielsen D., Schioler V., Skovsgaard T., and Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin. Chem. 42 4 (1996) 564-575
28. Pons-Anicet D.M., Krebs B.P., Mira R., and Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br. J. Cancer 55 5 (1987) 567-569
29. Dixon A.R., Jonrup I., Jackson L., Chan S.Y., Badley R.A., and Blamey R.W. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction?. Dis. Markers 9 3-4 (1991) 167-174
30. Robertson J.F., Pearson D., Price M.R., Selby C., Blamey R.W., and Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br. J. Cancer 64 4 (1991) 757-763
31. Basuyau J.P., Blanc-Vincent M.P., Bidart J.M., Daver A., Deneux L., Eche N., et al. Marqueurs tumoraux sériques du cancer du sein. Standards. Options et Recommandations. Bull Cancer 87 10 (2000) 723-737
32. Pavesi F., Lotzniker M., Scarabelli M., Mauro E., Visconti G., Nicolato E., et al. Circulating CA 549 and other associated antigens in breast cancer patients. Oncology 51 1 (1994) 18-21
33. Rodriguez de Paterna L., Arnaiz F., Estenoz J., Ortuno B., and Lanzos E. Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma. Int. J. Biol. Markers 10 1 (1995) 24-29
34. Vizcarra E., Lluch A., Cibrian R., Jarque F., Alberola V., Belloch V., et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res. Treat. 37 3 (1996) 209-216
35. Coveney E.C., Geraghty J.G., Sherry F., McDermott E.W., Fennelly J.J., O'Higgins N.J., et al. The clinical value of CEA and CA 15.3 in breast cancer management. Int. J. Biol. Markers 10 1 (1995) 35-41
36. Pectasides D., Pavlidis N., Gogou L., Antoniou F., Nicolaides C., and Tsikalakis D. Clinical value of CA 15.3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am. J. Clin. Oncol. 19 5 (1996) 459-464
37. Molina R., Zanon G., Filella X., Moreno F., Jo J., Daniels M., et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res. Treat. 36 1 (1995) 41-48
38. Vizcarra E., Lluch A., Cibrian R., Jarque F., and Garcia-Conde J. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology 51 6 (1994) 491-496
39. Nakata B., Ogawa Y., Ishikawa T., Ikeda K., Kato Y., Nishino H., et al. Serum Cyfra 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89 6 (2000) 1285-1290
40. Sias P.E., Kotts C.E., Vetterlein D., Shepard M., and Wong W.L. Elisa for quantitation of the extracellular domain of p185HER2 in biological fluids. J. Immunol. Methods 132 1 (1990) 73-80
41. Pichon M.F., Hacene K., Guepratte S., and Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clin. Lab. 50 3-4 (2004) 163-170
42. Fehm T., Maimonis P., Weitz S., Teramoto Y., Katalinic A., and Jager W. Influence of circulating c-erb B2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res. Treat. 43 1 (1997) 87-95
43. Meenakshi A., Kumar R.S., and Kumar N.S. Elisa for quantitation of serum c-erb B2 oncoprotein in breast cancer patients. J. Immunoassay Immunochem. 23 3 (2002) 293-305
44. Luftner D., Luke C., and Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin. Biochem. 36 4 (2003) 233-240
45. Fornier M.N., Seidman A.D., Schwartz M.K., Ghani F., Thiel R., Norton L., et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann. Oncol. 16 2 (2005) 234-239
46. Pallud C., Guinebretiere J.M., Guepratte S., Hacene K., Neumann R., Carney W., et al. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res. 25 2B (2005) 1433-1440
47. Saghatchian M., Guepratte S., Hacene K., Neumann R., Floiras J.L., and Pichon M.F. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int. J. Biol. Markers 19 1 (2004) 14-22
48. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., and Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem. 49 10 (2003) 1579-1598
49. Muller V., Witzel I., Luck H.J., Kohler G., von Minckwitz G., Mobus V., et al. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res. Treat. 86 1 (2004) 9-18
50. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., and Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10 24 (1982) 7895-7903
51. Ribieras S., Tomasetto C., and Rio M.C. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim. Biophys. Acta 1378 1 (1998) F61-F77
52. Spyratos F., Andrieu C., Hacene K., Chambon P., and Rio M.C. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br. J. Cancer 69 2 (1994) 394-397
53. Foekens J.A., van Putten W.L., Portengen H., Rodenburg C.J., Reubi J.C., Berns P.M., et al. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J. Steroid Biochem. Mol. Biol. 37 6 (1990) 815-821
54. Balleine R.L., and Clarke C.L. Expression of the oestrogen responsive protein pS2 in human breast cancer. Histol. Histopathol. 14 2 (1999) 571-578
55. Ruibal A., Nunez M.I., del Rio M., Arias J., Martinez M.I., Rabadan J., et al. [Clinical-biological differences between invasive ductal carcinomas and breast lobular carcinomas. Preliminary results]. Rev. Esp. Med. Nucl. 18 2 (1999) 84-87
56. Chenard M.P., Tomasetto C., Bellocq J.P., and Rio M.C. Urinary pS2/TFF1 levels in the management of hormonodependent breast carcinomas. Peptides 25 5 (2004) 737-743
57. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48 8 (2002) 1296-1304
58. Mathelin C., Cromer A., Wendling C., Tomasetto C., and Rio M.C. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res. Treat. 96 1 (2006) 83-90
59. Becker S., Cazares L.H., Watson P., Lynch H., Semmes O.J., Drake R.R., et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann. Surg. Oncol. 11 10 (2004) 907-914
60. Hu Y., Zhang S.Z., Yu J.K., Liu J., Zheng S., and Hu X. [Diagnostic application of serum protein pattern and artificial neural network software in breast cancer]. Ai Zheng 24 1 (2005) 67-71